ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENGN ENGENE HOLDINGS INC

Not Yet Opened 12-11 16:00:00 EST

8.92

+0.91

+11.36%

盘后8.85

-0.07-0.78%

16:42 EST

High8.99	Low7.75	Vol242.26K
Open8.04	D1 Closing8.01	Amplitude15.48%
Mkt Cap576.04M	Tradable Cap333.01M	Total Shares64.58M
T/O2.11M	T/O Rate0.65%	Tradable Shares37.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":8.92,"timestamp":1765486800000,"preClose":8.01,"halted":0,"volume":242261,"hourTrading":{"tag":"盘后","latestPrice":8.85,"preClose":8.92,"latestTime":"16:42 EST","volume":765,"amount":6815.42,"timestamp":1765489335898},"delay":0,"floatShares":37332800,"shares":64578200,"eps":-1.918109,"marketStatus":"Not Yet Opened","change":0.91,"latestTime":"12-11 16:00:00 EST","open":8.04,"high":8.99,"low":7.75,"amount":2107108.896741,"amplitude":0.154806,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.918109,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765530000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":8.01,"preHourTrading":{"tag":"盘前","latestPrice":8.4,"preClose":8.01,"latestTime":"09:03 EST","volume":5,"amount":41.72,"timestamp":1765461816947},"postHourTrading":{"tag":"盘后","latestPrice":8.85,"preClose":8.92,"latestTime":"16:42 EST","volume":765,"amount":6815.42,"timestamp":1765489335898},"volumeRatio":0.779032},"requestUrl":"/m/hq/s/ENGN/wiki","defaultTab":"wiki","newsList":[{"id":"2588056337","title":"EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056337","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056337?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:44","pubTimestamp":1764683062,"startTime":"0","endTime":"0","summary":"EnGene (ENGN) said Tuesday that the US Food and Drug Administration selected detalimogene for its chemistry, manufacturing and controls development and readiness pilot program.Detalimogene is an inves","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2588555320","title":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588555320","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588555320?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:18","pubTimestamp":1764681501,"startTime":"0","endTime":"0","summary":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing ReadinessDec 2 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE’S DETALIMOGENE SELECTED FOR FDA MANUFACTU","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588058033","title":"enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058033","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058033?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:47","pubTimestamp":1764679656,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. has announced positive preliminary results from the pivotal cohort of its LEGEND trial studying detalimogene voraplasmid  in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer  with carcinoma in situ  with or without concomitant papillary disease. The results showed an improved complete response rate of 62% at six months. Safety data from 125 patients demonstrated a favorable tolerability profile, with low rates of treatment-related adverse events (42%) and dose interruptions . The company has not specified if these results have already been presented at a scientific meeting or will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL4149Bc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588676058","title":"enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588676058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588676058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588058972","title":"enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls  Development & Readiness Pilot Pprogram","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058972?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2586535478","title":"enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586535478","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586535478?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073816,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc., a clinical-stage genetic medicines company, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. Chief Strategy and Operations Officer Alex Nichols, Ph.D., is scheduled to deliver the presentation, which will be accessible via webcast on the enGene website and archived for 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6xsmTn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4127","ENGN","PIPR"],"gpt_icon":0},{"id":"2584924674","title":"enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924674","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924674?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573315,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - enGene Holdings Inc ::*ENGENE HOLDINGS FILES FOR OFFERING OF COMMON SHARES, SIZE NOT DISCLOSED - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-NOV-202521:55:30 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDb5dKf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583055325","title":"enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583055325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583055325?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:21","pubTimestamp":1763122901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ169:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583065095","title":"enGene Holdings (ENGN) Valuation in Focus Following Promising Phase 2 Bladder Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583065095","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583065095?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:21","pubTimestamp":1763119319,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) is drawing attention after announcing positive preliminary results from the pivotal cohort of its Phase 2 LEGEND trial. The data showed a high complete response rate and a favorable safety profile in challenging bladder cancer cases.\nSee our latest analysis for enGene Holdings.\nenGene Holdings’ impressive momentum really kicked in after its recent LEGEND trial data sent the stock soaring, highlighted by a 40% seven-day share price return and a staggering 129% gain over...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/engene-holdings-engn-valuation-in-focus-following-promising","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/engene-holdings-engn-valuation-in-focus-following-promising","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ENGN","DCF"],"gpt_icon":0},{"id":"2583807595","title":"Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Expected Economic Data Gaps","url":"https://stock-news.laohu8.com/highlight/detail?id=2583807595","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583807595?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:57","pubTimestamp":1763042229,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% lower in Thursday's premarket activity as investors weighed th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"70eb9cd7cf3b474dd15e72f3f7c2341c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":[".IXIC","IYW","DDS","VDC","EQR","IGV","XLP","XLV","IYJ","USO","IBB","ENGN","IYH","EETH",".DJI","RTH","XLK","IYK","SPY","BITO","BWEN","RTH.AU","XLI","FAZ","EEM","XLF","VHT.AU","ARX","XLE","XRT","VHT","SOXX","ARX.AU","BETH","CSCO","VIS","XLY","TTE","PMR","IGM","UNG","FAS","XSD","IYE","SPY.AU","IVV"],"gpt_icon":1},{"id":"2583523395","title":"EnGene Prices $130 Million Offering of Common Shares, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523395","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523395?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:37","pubTimestamp":1763023020,"startTime":"0","endTime":"0","summary":"EnGene  said Thursday it priced an underwritten public offering of 12.6 million shares at $8.50 per share and pre-funded warrants to purchase 2.7 million shares at $8.4999 per warrant for total expected gross proceeds of $130 million.The underwriters were granted a 30-day option to purchase up to 2.3 million additional shares.Closing of the offering is expected to occur on or about Friday, subject to customary closing conditions, the company said.Shares were 4.2% lower in premarket trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583537820","title":"BRIEF-Engene Holdings Prices 12,558,823 Common Shares At $8.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583537820","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583537820?lang=en_us&edition=fundamental","pubTime":"2025-11-13 13:28","pubTimestamp":1763011713,"startTime":"0","endTime":"0","summary":"BRIEF-Engene Holdings Prices 12,558,823 Common Shares At $8.50 Per ShareNov 13 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE HOLDINGS INC  -  PRICING OF 12,558,823 COMMON SHARES AT A PUBLIC OFFERING P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WO1N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583553782","title":"enGene Holdings Inc  -  Pricing of 12,558,823 Common Shares at a Public Offering Price of $8.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583553782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583553782?lang=en_us&edition=fundamental","pubTime":"2025-11-13 13:27","pubTimestamp":1763011660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WO1N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583053104","title":"Could a Shift in enGene (ENGN) Trial Endpoints Reveal New Priorities in Its Clinical Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583053104","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583053104?lang=en_us&edition=fundamental","pubTime":"2025-11-13 09:29","pubTimestamp":1762997381,"startTime":"0","endTime":"0","summary":"enGene Holdings recently reported additional preliminary efficacy data from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, along with a protocol amendment changing the primary clinical endpoint after discussions with the FDA.\nThis update reveals that earlier patients in the study experienced a lower 12-month complete response rate compared to FDA-approved therapies, leading to significant...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/could-a-shift-in-engene-engn-trial-endpoints-reveal-new-prio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/could-a-shift-in-engene-engn-trial-endpoints-reveal-new-prio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583581618","title":"EnGene Launches Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583581618","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583581618?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:53","pubTimestamp":1762988026,"startTime":"0","endTime":"0","summary":"EnGene (ENGN) said late Wednesday it launched an underwritten public offering of common shares.The company plans to offer underwriters a 30-day overallotment option to buy up to an additional 15% of the shares offered, according to a statement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583810586","title":"BRIEF-enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583810586","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583810586?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:55","pubTimestamp":1762984530,"startTime":"0","endTime":"0","summary":"BRIEF-enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC FilingNov 12  - enGene Holdings Inc ENGN.O:ENGENE HOLDINGS FILES FOR OFFERING OF COMMON SHARES, SIZE NOT DISCLOSED - SEC FILINGSource text: [ID:n0001193125-25-277833]Further company coverage: ENGN.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583585007","title":"enGene Holdings Files for Offering of Common Shares, Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583585007","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583585007?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:53","pubTimestamp":1762984425,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583458821","title":"enGene Announces Proposed Public Offering Of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583458821","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583458821?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:12","pubTimestamp":1762981968,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - enGene Holdings Inc ::*ENGENE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-NOV-202521:01:00.337 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nRSD2cmKQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2582837746","title":"enGene Holdings Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2582837746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582837746?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:27","pubTimestamp":1762957620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 09:27 ET (14:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2582792533","title":"UBS Boosts Price Target on enGene Holdings to $10 From $4, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582792533","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582792533?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952420,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) has an average rating of buy and mean price target of $23.70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.engene.com","stockEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":0.3328},{"period":"3month","weight":0.3218},{"period":"6month","weight":1.4054},{"period":"1year","weight":0.0114},{"period":"ytd","weight":0.2045}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.","exchange":"NASDAQ","name":"ENGENE HOLDINGS INC","nameEN":"ENGENE HOLDINGS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENGENE HOLDINGS INC,ENGN,ENGENE HOLDINGS INC股票,ENGENE HOLDINGS INC股票老虎,ENGENE HOLDINGS INC股票老虎国际,ENGENE HOLDINGS INC行情,ENGENE HOLDINGS INC股票行情,ENGENE HOLDINGS INC股价,ENGENE HOLDINGS INC股市,ENGENE HOLDINGS INC股票价格,ENGENE HOLDINGS INC股票交易,ENGENE HOLDINGS INC股票购买,ENGENE HOLDINGS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction